ZGC TEC LEASING (01601) enters into a finance lease agreement with Shanxi Jingjin Feipeng Energy Technology
ZGC TEC LEASING (01601) announced that on November 4, 2026, the Company, as lessor, entered into Finance Lease Agreement III with the lessee (Shanxi Jingjin Feipeng Energy Technology Co., Ltd.), pursuant to which the lessor will purchase the lessee's own leased assets III for a transfer price of RMB60 million; and the lessor will lease the leased assets III back to the lessee for a lease term of 72 months, with total lease payments of approximately RMB71.05 million. The leased assets III are equipment related to the independent energy storage business.
ZGC TEC LEASING (01601) announced that on November 4, 2026, the Company, as lessor, entered into Finance Lease Agreement III with the lessee (Shanxi Jingjin Feipeng Energy Technology Co., Ltd.), pursuant to which the lessor will purchase the lessee's own leased assets III at a transfer price of RMB60 million; and the lessor will lease leased assets III back to the lessee for a lease term of 72 months, with total lease payments of approximately RMB71.05 million. Leased assets III are equipment related to the independent energy storage business.
Related Articles
US Stock Market Move | Alibaba Group Holding Limited Sponsored ADR (BABA.US) rose more than 6% as Apple Inc.'s intelligence features for the China market began testing, opening new opportunities for Qwen.
KPA-BM HLDGS (02663) changes controlling shareholder, receives a general offer at a discount of approximately 13.8%, trading resumes on November 5.
MICOT PHARMA-B (02335) received the first project funding under the National Science and Technology Major Project and obtained ethics approval from the lead site for the Phase III clinical trial of MT200605.
US Stock Market Move | Alibaba Group Holding Limited Sponsored ADR (BABA.US) rose more than 6% as Apple Inc.'s intelligence features for the China market began testing, opening new opportunities for Qwen.
KPA-BM HLDGS (02663) changes controlling shareholder, receives a general offer at a discount of approximately 13.8%, trading resumes on November 5.
MICOT PHARMA-B (02335) received the first project funding under the National Science and Technology Major Project and obtained ethics approval from the lead site for the Phase III clinical trial of MT200605.
